Fierce Healthcare August 30, 2023
The Biden administration and federal regulators may be taking a victory lap following the unveiling of the Centers for Medicare & Medicaid Services’ (CMS’) price negotiations list, but major players in the pharmaceutical industry feel the White House overstepped and think innovation will be stifled, ultimately leading to the creation of fewer life-changing drugs.
Tuesday, CMS revealed that Eliquis, Xarelto, Jardiance and Januvia were among the drugs selected for price negotiations. Nearly 7.5 million Medicare Part D beneficiaries used one of those drugs between June 2022 and May 2023, the agency said.
Total gross cost amounts to more than $33 billion for those four drugs alone.
Organizations representing the biotech and pharma industries released strong statements opposing...
Today's Sponsors
Today's Sponsor